Target Name: RBM39
NCBI ID: G9584
Review Report on RBM39 Target / Biomarker Content of Review Report on RBM39 Target / Biomarker
RBM39
Other Name(s): Splicing factor HCC1 | DKFZp781C0423 | epididymis secretory sperm binding protein | CC1.3 | functional spliceosome-associated protein 59 | Functional spliceosome-associated protein 59 | CAPER alpha | RNA-binding motif protein 39 | splicing factor HCC1 | RBM39 variant 1 | CAPER | OTTHUMP00000063388 | RNPC2 | RBM39_HUMAN | CAPERalpha | FLJ44170 | hepatocellular carcinoma protein 1 | Hepatocellular carcinoma protein 1 | RNA-binding protein 39 | FSAP59 | Coactivator of activating protein-1 and estrogen receptors | fSAP59 | Splicing factor CC1.3 | RNA binding motif protein 39, transcript variant 1 | RNA-binding region (RNP1, RRM) containing 2 | RNA binding motif protein 39 | CC1.4 | coactivator of activating protein-1 and estrogen receptors | RNA-binding region-containing protein 2 | HCC1 | RNA-binding protein 39 (isoform a) | OTTHUMP00000196683

RBM39: A Non-Coding RNA Molecule Regulating Splicing and Cancer Development

RBM39 (splicing factor HCC1) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms, including humans. It is a key player in the process of splicing, which is the process by which the cell removes non-coding DNA sequences from the RNA molecule and joins together the remaining coding DNA sequences to create a functional protein.

RBM39 is a protein that is expressed in various tissues and cells of the body, including the brain, heart, and blood vessels. It is highly conserved across different species, which suggests that it is a fundamental regulator of gene expression that is involved in many different biological processes.

Drug Targeting

RBM39 is a drug target of great interest because of its involvement in various diseases, including cancer. Studies have shown that RBM39 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, RBM39 has been shown to promote the growth and survival of cancer cells, which suggests that it may be a potential drug target.

One of the challenges in targeting RBM39 is its high expression level in various tissues, which makes it difficult to selectively target it. However, recent studies have identified potential small molecule inhibitors that can specifically target RBM39, which may be useful for drug development.

Biomarker

RBM39 is also a potential biomarker for various diseases, including cancer. Its high expression level and its involvement in the regulation of gene expression make it an attractive candidate for use as a diagnostic or predictive marker for cancer.

Studies have shown that RBM39 is downregulated in various types of cancer, which suggests that it may be a potential target for cancer therapies. Additionally, because RBM39 is highly conserved across different species, it is a potential candidate for use as a biomarker for various diseases, including cancer.

Conclusion

RBM39 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in various organisms. Its high expression level and its involvement in the regulation of splicing make it a potential drug target and a promising biomarker for various diseases, including cancer. Further research is needed to fully understand the role of RBM39 in gene expression and its potential as a drug target and biomarker.

Protein Name: RNA Binding Motif Protein 39

Functions: RNA-binding protein that acts as a pre-mRNA splicing factor (PubMed:15694343, PubMed:31271494, PubMed:28437394, PubMed:28302793, PubMed:24795046). Acts by promoting exon inclusion via regulation of exon cassette splicing (PubMed:31271494). Also acts as a transcriptional coactivator for steroid nuclear receptors ESR1/ER-alpha and ESR2/ER-beta, and JUN/AP-1, independently of the pre-mRNA splicing factor activity (By similarity)

The "RBM39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK | RECQL | RECQL4 | RECQL5 | REELD1 | REEP1 | REEP2 | REEP3 | REEP4